Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR

Area of Science:

• Urology
• Oncology
• Molecular Biology

Background:

• Accurate diagnosis and targeted therapy for prostate carcinoma (PCa) require understanding gene expression in malignant and non-malignant tissues.
• Established PCa markers like prostate-specific antigen (PSA) and human kallikrein 2 (hK2) have limitations.
• Novel markers such as prostate stem cell antigen (PSCA) and transient receptor potential p8 (TRP-P8) warrant investigation.

Purpose of the Study:

• To compare the mRNA expression of PSCA and TRP-P8 with PSA and hK2 in PCa.
• To evaluate the diagnostic and staging potential of these markers.
• To identify novel biomarkers for PCa diagnosis and therapy.

Main Methods:

• Quantitative real-time RT-PCR assays were performed on matched tissue specimens from 40 primary PCa patients.
• Specific assays were developed for PSA, hK2, TRP-P8, and PSCA mRNA expression.
• Analysis focused on comparing transcript levels between malignant and non-malignant tissues and across tumor stages.

Main Results:

• PSA exhibited the highest transcript levels, followed by hK2, TRP-P8, and PSCA.
• Relative mRNA levels of PSA, hK2, and TRP-P8 were elevated in malignant versus non-malignant tissues.
• Only TRP-P8 showed a statistically significant increase in malignant tissues; its expression also differentiated tumor stages.

Conclusions:

• Quantitative mRNA expression analysis offers potential for differential diagnosis and molecular staging of PCa.
• TRP-P8 demonstrates significant upregulation in PCa and is a promising prostate-specific marker.
• TRP-P8 qualifies as a potential target for targeted therapies in prostate cancer.